Literature DB >> 11108890

Occurrence, regulation, and significance of progesterone receptors in human meningioma.

M A Blankenstein1, F M Verheijen, J M Jacobs, T H Donker, M W van Duijnhoven, J H Thijssen.   

Abstract

The abundant expression of progesterone receptors (PR) in human meningiomas is well established. It is unknown, however, how PR expression is regulated, especially since estrogen receptors (ER) are virtually absent in these tumors. At the mRNA level, ER splice variants occur in meningioma but these appear not to be involved in the apparently autonomous PR expression. In an earlier study, because other ER-inducible proteins were either not expressed at all (pS2) or were expressed at a very low level compared to their expression in breast cancer (Cathepsin-D), the authors have postulated that the autonomous PR expression in meningioma is PR promoter-related rather than ER-related and have studied PR expression in cultured meningioma cells. PR levels appeared to decrease rapidly in vitro in monolayer as well as in three dimensional spheroid cultures. Culture conditions thus are not yet sufficient for the quantitative evaluation of PR expression. To evaluate whether PR deterioration is associated with cell turnover (meningiomas grow much faster in vitro than in vivo), the relationship between expression of the apoptotic proteins Bcl-2 and Bax and PR expression was investigated. Bcl-2 expression was found to be highest in meningioma with low PR levels, and in breast cancer tissue with high PR levels. Bax expression was not related to PR expression in any of the two tissues. Given the potential benefit of antiprogestin treatment and the occurrence in meningiomas of a protein capable of binding to the estrogen-responsive element, the expression of PR in meningioma remains a fascinating phenomenon which requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11108890     DOI: 10.1016/s0039-128x(00)00193-8

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  16 in total

Review 1.  Breast carcinoma metastasis to meningioma in the thoracic spine: A case report and review of the literature.

Authors:  Eijiro Okada; Masaya Nakamura; Yoshitomo Koshida; Kiyoshi Mukai; Yoshiaki Toyama; Morio Matsumoto
Journal:  J Spinal Cord Med       Date:  2014-03-12       Impact factor: 1.985

2.  Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas.

Authors:  Thomas Graillon; Céline Defilles; Amira Mohamed; Christophe Lisbonis; Anne-Laure Germanetti; Olivier Chinot; Dominique Figarella-Branger; Pierre-Hugues Roche; Tarek Adetchessi; Stéphane Fuentes; Philippe Metellus; Henry Dufour; Alain Enjalbert; Anne Barlier
Journal:  J Neurooncol       Date:  2015-05-27       Impact factor: 4.130

3.  Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays.

Authors:  Mark A Watson; David H Gutmann; Kelly Peterson; Michael R Chicoine; Bette K Kleinschmidt-DeMasters; Henry G Brown; Arie Perry
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

4.  Abrupt regression of a meningioma after discontinuation of cyproterone treatment.

Authors:  A M G Gonçalves; P Page; V Domigo; J-F Méder; C Oppenheim
Journal:  AJNR Am J Neuroradiol       Date:  2010-01-06       Impact factor: 3.825

5.  The prognostic value of progesterone receptor status in meningiomas.

Authors:  F Roser; M Nakamura; M Bellinzona; S K Rosahl; H Ostertag; M Samii
Journal:  J Clin Pathol       Date:  2004-10       Impact factor: 3.411

6.  Meningioma in untreated congenital adrenal hyperplasia: a relationship?

Authors:  Annemieke C Heijboer; J Coen Netelenbos; Marinus A Blankenstein
Journal:  J Neurooncol       Date:  2008-11-28       Impact factor: 4.130

7.  The treatment of malignant meningioma with verotoxin.

Authors:  Bodour Salhia; James T Rutka; Clifford Lingwood; Anita Nutikka; Wouter R Van Furth
Journal:  Neoplasia       Date:  2002 Jul-Aug       Impact factor: 5.715

8.  Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.

Authors:  Yongli Ji; Cathryn Rankin; Steven Grunberg; Andy E Sherrod; Jamshid Ahmadi; Jeannette J Townsend; Lynn G Feun; Ruth K Fredericks; Christy A Russell; Fairooz F Kabbinavar; Keith J Stelzer; Anne Schott; Claire Verschraegen
Journal:  J Clin Oncol       Date:  2015-11-02       Impact factor: 44.544

9.  Reproductive factors and risk of primary brain tumors in women.

Authors:  Gabriella M Anic; Melissa H Madden; L Burton Nabors; Jeffrey J Olson; Renato V LaRocca; Zachary J Thompson; Shitaldas J Pamnani; Peter A Forsyth; Reid C Thompson; Kathleen M Egan
Journal:  J Neurooncol       Date:  2014-04-04       Impact factor: 4.130

10.  Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature.

Authors:  Stefan Wolfsberger; Soroush Doostkam; Hans-Gerd Boecher-Schwarz; Karl Roessler; Michael van Trotsenburg; Johannes A Hainfellner; Engelbert Knosp
Journal:  Neurosurg Rev       Date:  2004-05-27       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.